Metabolic interventions to enhance immunotherapy and targeted therapy efficacy in advanced colorectal cancer
Curr Opin Chem Biol. 2023 Oct 6;77:102401. doi: 10.1016/j.cbpa.2023.102401. Online ahead of print.ABSTRACTCurrent standard-of-care for metastatic colorectal cancer patients includes chemotherapy and anti-angiogenic or anti-epidermal growth factor receptor for microsatellite stable tumors and pembrolizumab for microsatellite instable tumors. However, despite the available therapies, the prognosis remains poor. In recent years, new drugs combined with immune checkpoint inhibitors have been tested in microsatellite stable metastatic colorectal cancer patients, but the benefit was modest. Here, we review the metabolic interact...
Source: Current Opinion in Chemical Biology - October 8, 2023 Category: Biochemistry Authors: Helena Oliveres Marta Cascante Joan Maurel Source Type: research

Metabolic interventions to enhance immunotherapy and targeted therapy efficacy in advanced colorectal cancer
Curr Opin Chem Biol. 2023 Oct 6;77:102401. doi: 10.1016/j.cbpa.2023.102401. Online ahead of print.ABSTRACTCurrent standard-of-care for metastatic colorectal cancer patients includes chemotherapy and anti-angiogenic or anti-epidermal growth factor receptor for microsatellite stable tumors and pembrolizumab for microsatellite instable tumors. However, despite the available therapies, the prognosis remains poor. In recent years, new drugs combined with immune checkpoint inhibitors have been tested in microsatellite stable metastatic colorectal cancer patients, but the benefit was modest. Here, we review the metabolic interact...
Source: Current Opinion in Chemical Biology - October 8, 2023 Category: Biochemistry Authors: Helena Oliveres Marta Cascante Joan Maurel Source Type: research

Metabolic interventions to enhance immunotherapy and targeted therapy efficacy in advanced colorectal cancer
Curr Opin Chem Biol. 2023 Oct 6;77:102401. doi: 10.1016/j.cbpa.2023.102401. Online ahead of print.ABSTRACTCurrent standard-of-care for metastatic colorectal cancer patients includes chemotherapy and anti-angiogenic or anti-epidermal growth factor receptor for microsatellite stable tumors and pembrolizumab for microsatellite instable tumors. However, despite the available therapies, the prognosis remains poor. In recent years, new drugs combined with immune checkpoint inhibitors have been tested in microsatellite stable metastatic colorectal cancer patients, but the benefit was modest. Here, we review the metabolic interact...
Source: Current Opinion in Chemical Biology - October 8, 2023 Category: Biochemistry Authors: Helena Oliveres Marta Cascante Joan Maurel Source Type: research

Metabolic interventions to enhance immunotherapy and targeted therapy efficacy in advanced colorectal cancer
Curr Opin Chem Biol. 2023 Oct 6;77:102401. doi: 10.1016/j.cbpa.2023.102401. Online ahead of print.ABSTRACTCurrent standard-of-care for metastatic colorectal cancer patients includes chemotherapy and anti-angiogenic or anti-epidermal growth factor receptor for microsatellite stable tumors and pembrolizumab for microsatellite instable tumors. However, despite the available therapies, the prognosis remains poor. In recent years, new drugs combined with immune checkpoint inhibitors have been tested in microsatellite stable metastatic colorectal cancer patients, but the benefit was modest. Here, we review the metabolic interact...
Source: Current Opinion in Chemical Biology - October 8, 2023 Category: Biochemistry Authors: Helena Oliveres Marta Cascante Joan Maurel Source Type: research

Metabolic interventions to enhance immunotherapy and targeted therapy efficacy in advanced colorectal cancer
Curr Opin Chem Biol. 2023 Oct 6;77:102401. doi: 10.1016/j.cbpa.2023.102401. Online ahead of print.ABSTRACTCurrent standard-of-care for metastatic colorectal cancer patients includes chemotherapy and anti-angiogenic or anti-epidermal growth factor receptor for microsatellite stable tumors and pembrolizumab for microsatellite instable tumors. However, despite the available therapies, the prognosis remains poor. In recent years, new drugs combined with immune checkpoint inhibitors have been tested in microsatellite stable metastatic colorectal cancer patients, but the benefit was modest. Here, we review the metabolic interact...
Source: Current Opinion in Chemical Biology - October 8, 2023 Category: Biochemistry Authors: Helena Oliveres Marta Cascante Joan Maurel Source Type: research

Metabolic interventions to enhance immunotherapy and targeted therapy efficacy in advanced colorectal cancer
Curr Opin Chem Biol. 2023 Oct 6;77:102401. doi: 10.1016/j.cbpa.2023.102401. Online ahead of print.ABSTRACTCurrent standard-of-care for metastatic colorectal cancer patients includes chemotherapy and anti-angiogenic or anti-epidermal growth factor receptor for microsatellite stable tumors and pembrolizumab for microsatellite instable tumors. However, despite the available therapies, the prognosis remains poor. In recent years, new drugs combined with immune checkpoint inhibitors have been tested in microsatellite stable metastatic colorectal cancer patients, but the benefit was modest. Here, we review the metabolic interact...
Source: Current Opinion in Chemical Biology - October 8, 2023 Category: Biochemistry Authors: Helena Oliveres Marta Cascante Joan Maurel Source Type: research

Metabolic interventions to enhance immunotherapy and targeted therapy efficacy in advanced colorectal cancer
Curr Opin Chem Biol. 2023 Oct 6;77:102401. doi: 10.1016/j.cbpa.2023.102401. Online ahead of print.ABSTRACTCurrent standard-of-care for metastatic colorectal cancer patients includes chemotherapy and anti-angiogenic or anti-epidermal growth factor receptor for microsatellite stable tumors and pembrolizumab for microsatellite instable tumors. However, despite the available therapies, the prognosis remains poor. In recent years, new drugs combined with immune checkpoint inhibitors have been tested in microsatellite stable metastatic colorectal cancer patients, but the benefit was modest. Here, we review the metabolic interact...
Source: Current Opinion in Chemical Biology - October 8, 2023 Category: Biochemistry Authors: Helena Oliveres Marta Cascante Joan Maurel Source Type: research

Metabolic interventions to enhance immunotherapy and targeted therapy efficacy in advanced colorectal cancer
Curr Opin Chem Biol. 2023 Oct 6;77:102401. doi: 10.1016/j.cbpa.2023.102401. Online ahead of print.ABSTRACTCurrent standard-of-care for metastatic colorectal cancer patients includes chemotherapy and anti-angiogenic or anti-epidermal growth factor receptor for microsatellite stable tumors and pembrolizumab for microsatellite instable tumors. However, despite the available therapies, the prognosis remains poor. In recent years, new drugs combined with immune checkpoint inhibitors have been tested in microsatellite stable metastatic colorectal cancer patients, but the benefit was modest. Here, we review the metabolic interact...
Source: Current Opinion in Chemical Biology - October 8, 2023 Category: Biochemistry Authors: Helena Oliveres Marta Cascante Joan Maurel Source Type: research

Nutritional metabolomics: Recent developments and future needs
Curr Opin Chem Biol. 2023 Oct 5;77:102400. doi: 10.1016/j.cbpa.2023.102400. Online ahead of print.ABSTRACTMetabolomics has rapidly been adopted as one of the key methods in nutrition research. This review focuses on the recent developments and updates in the field, including the analytical methodologies that encompass improved instrument sensitivity, sampling techniques and data integration (multiomics). Metabolomics has advanced the discovery and validation of dietary biomarkers and their implementation in health research. Metabolomics has come to play an important role in the understanding of the role of small molecules ...
Source: Current Opinion in Chemical Biology - October 7, 2023 Category: Biochemistry Authors: Maaria Kortesniemi Stefania Noerman Anna K årlund Jasmin Raita Topi Meuronen Ville Koistinen Rikard Landberg Kati Hanhineva Source Type: research

Nutritional metabolomics: Recent developments and future needs
Curr Opin Chem Biol. 2023 Oct 5;77:102400. doi: 10.1016/j.cbpa.2023.102400. Online ahead of print.ABSTRACTMetabolomics has rapidly been adopted as one of the key methods in nutrition research. This review focuses on the recent developments and updates in the field, including the analytical methodologies that encompass improved instrument sensitivity, sampling techniques and data integration (multiomics). Metabolomics has advanced the discovery and validation of dietary biomarkers and their implementation in health research. Metabolomics has come to play an important role in the understanding of the role of small molecules ...
Source: Current Opinion in Chemical Biology - October 7, 2023 Category: Biochemistry Authors: Maaria Kortesniemi Stefania Noerman Anna K årlund Jasmin Raita Topi Meuronen Ville Koistinen Rikard Landberg Kati Hanhineva Source Type: research

Immunomodulatory roles of PARPs: Shaping the tumor microenvironment, one ADP-ribose at a time
Curr Opin Chem Biol. 2023 Oct 4;77:102402. doi: 10.1016/j.cbpa.2023.102402. Online ahead of print.ABSTRACTPARPs encompass a small yet pervasive group of 17 enzymes that catalyze a post-translational modification known as ADP-ribosylation. PARP1, the founding member, has received considerable focus; however, in recent years, the spotlight has shifted to other members within the PARP family. In this opinion piece, we first discuss surprising findings that some FDA-approved PARP1 inhibitors activate innate immune signaling in cancer cells that harbor mutations in the DNA repair pathway. We then discuss hot-off-the-press genet...
Source: Current Opinion in Chemical Biology - October 6, 2023 Category: Biochemistry Authors: Deja M Brooks Sudarshan Anand Michael S Cohen Source Type: research

Immunomodulatory roles of PARPs: Shaping the tumor microenvironment, one ADP-ribose at a time
Curr Opin Chem Biol. 2023 Oct 4;77:102402. doi: 10.1016/j.cbpa.2023.102402. Online ahead of print.ABSTRACTPARPs encompass a small yet pervasive group of 17 enzymes that catalyze a post-translational modification known as ADP-ribosylation. PARP1, the founding member, has received considerable focus; however, in recent years, the spotlight has shifted to other members within the PARP family. In this opinion piece, we first discuss surprising findings that some FDA-approved PARP1 inhibitors activate innate immune signaling in cancer cells that harbor mutations in the DNA repair pathway. We then discuss hot-off-the-press genet...
Source: Current Opinion in Chemical Biology - October 6, 2023 Category: Biochemistry Authors: Deja M Brooks Sudarshan Anand Michael S Cohen Source Type: research

Global approaches for protein thiol redox state detection
Curr Opin Chem Biol. 2023 Oct 3;77:102390. doi: 10.1016/j.cbpa.2023.102390. Online ahead of print.ABSTRACTDue to its nucleophilicity, the thiol group of cysteine is chemically very versatile. Hence, cysteine often has important functions in a protein, be it as the active site or, in extracellular proteins, as part of a structural disulfide. Within the cytosol, cysteines are typically reduced. But the nucleophilicity of its thiol group makes it also particularly prone to post-translational oxidative modifications. These modifications often lead to an alteration of the function of the affected protein and are reversible in v...
Source: Current Opinion in Chemical Biology - October 5, 2023 Category: Biochemistry Authors: Lisa R Knoke Lars I Leichert Source Type: research

Editorial overview: Imaging metal ions in biological systems
Curr Opin Chem Biol. 2023 Oct 1;77:102388. doi: 10.1016/j.cbpa.2023.102388. Online ahead of print.NO ABSTRACTPMID:37788545 | DOI:10.1016/j.cbpa.2023.102388 (Source: Current Opinion in Chemical Biology)
Source: Current Opinion in Chemical Biology - October 3, 2023 Category: Biochemistry Authors: Daniela Buccella Christoph J Fahrni Source Type: research

Editorial overview: Imaging metal ions in biological systems
Curr Opin Chem Biol. 2023 Oct 1;77:102388. doi: 10.1016/j.cbpa.2023.102388. Online ahead of print.NO ABSTRACTPMID:37788545 | DOI:10.1016/j.cbpa.2023.102388 (Source: Current Opinion in Chemical Biology)
Source: Current Opinion in Chemical Biology - October 3, 2023 Category: Biochemistry Authors: Daniela Buccella Christoph J Fahrni Source Type: research